Literature DB >> 8484748

Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

T Wisniewski1, A Golabek, E Matsubara, J Ghiso, B Frangione.   

Abstract

Apolipoprotein E (apo E) is associated with Alzheimer's beta-amyloid (A beta) in senile plaques. A beta is now known to be a normal soluble peptide (sA beta) found in the cerebrospinal fluid (CSF) and other biological fluids. We have used synthetic A beta peptides bound to affinity membranes in order to determine whether apo E or any other amyloid associated protein will bind to these membranes, when they are bathed in CSF. Under these conditions apo E, as well as another apolipoprotein, apolipoprotein J (Apo J), bound to the membranes. Using ELISA and ligand binding studies, we found a high avidity binding of A beta peptides to apo E. This suggests that apo E, as well as other related proteins may bind not only amyloid A beta but also sA beta. This interaction may be critical in amyloid formation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484748     DOI: 10.1006/bbrc.1993.1423

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  74 in total

1.  Measurement of apolipoprotein E (apoE) in cerebrospinal fluid.

Authors:  C Hesse; H Larsson; P Fredman; L Minthon; N Andreasen; P Davidsson; K Blennow
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

2.  Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

Authors:  C Haas; P Cazorla; C D Miguel; F Valdivieso; J Vázquez
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families.

Authors:  Elizabeth E Marchani; Thomas D Bird; Ellen J Steinbart; Elisabeth Rosenthal; Chang-En Yu; Gerard D Schellenberg; Ellen M Wijsman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

4.  A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type.

Authors:  Eleanna Kara; Jordan D Marks; Allyson D Roe; Caitlin Commins; Zhanyun Fan; Maria Calvo-Rodriguez; Susanne Wegmann; Eloise Hudry; Bradley T Hyman
Journal:  J Biol Chem       Date:  2018-06-27       Impact factor: 5.157

Review 5.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 6.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

Review 7.  A potential role for apoptosis in neurodegeneration and Alzheimer's disease.

Authors:  C W Cotman; A J Anderson
Journal:  Mol Neurobiol       Date:  1995-02       Impact factor: 5.590

Review 8.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

9.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Late onset Alzheimer's disease and apolipoprotein association in the Irish population: relative risk and attributable fraction.

Authors:  Z Hawi; K Sheehan; A Lynch; I Evans; N Lowe; B Lawlor; M Gill
Journal:  Ir J Med Sci       Date:  2003 Apr-Jun       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.